IN2015MN00002A - - Google Patents
Info
- Publication number
- IN2015MN00002A IN2015MN00002A IN2MUN2015A IN2015MN00002A IN 2015MN00002 A IN2015MN00002 A IN 2015MN00002A IN 2MUN2015 A IN2MUN2015 A IN 2MUN2015A IN 2015MN00002 A IN2015MN00002 A IN 2015MN00002A
- Authority
- IN
- India
- Prior art keywords
- stereoisomer
- amenable
- disorders
- inhibiting
- prevention
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN2MUN2015 IN2015MN00002A (fr) | 2012-07-09 | 2013-07-09 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN762KO2012 | 2012-07-09 | ||
IN2MUN2015 IN2015MN00002A (fr) | 2012-07-09 | 2013-07-09 | |
PCT/IB2013/055618 WO2014009872A1 (fr) | 2012-07-09 | 2013-07-09 | Dérivés tétrahydroquinazolinone utilisés comme inhibiteurs de parp |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2015MN00002A true IN2015MN00002A (fr) | 2015-10-16 |
Family
ID=48906465
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN2MUN2015 IN2015MN00002A (fr) | 2012-07-09 | 2013-07-09 |
Country Status (8)
Country | Link |
---|---|
US (1) | US9359367B2 (fr) |
EP (1) | EP2870140B8 (fr) |
AU (1) | AU2013288265B2 (fr) |
CA (1) | CA2877826C (fr) |
ES (1) | ES2595240T3 (fr) |
IN (1) | IN2015MN00002A (fr) |
WO (1) | WO2014009872A1 (fr) |
ZA (1) | ZA201409497B (fr) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2015245786B2 (en) | 2014-04-10 | 2018-03-15 | Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. | Analogues of 4H-pyrazolo[1,5-a]benzimidazole compound as PARP inhibitors |
WO2016012956A1 (fr) * | 2014-07-24 | 2016-01-28 | Lupin Limited | Dérivés d'isoquinolinone utilisés en tant qu'inhibiteurs de parp |
WO2017013593A1 (fr) | 2015-07-22 | 2017-01-26 | Lupin Limited | Dérivés d'isoquinolinone utilisés en tant qu'inhibiteurs de parp |
KR20180037265A (ko) * | 2015-08-17 | 2018-04-11 | 루핀 리미티드 | Parp 억제제로서의 헤테로아릴 유도체 |
CN108822115B (zh) * | 2017-04-21 | 2022-08-12 | 上海迪诺医药科技有限公司 | 一种抑制parp活性的化合物的制备方法及其中间体 |
HUE061595T2 (hu) | 2017-12-21 | 2023-07-28 | Ribon Therapeutics Inc | Kinazolinonok mint PARP14 inhibitorok |
CN111269216A (zh) * | 2018-12-05 | 2020-06-12 | 中国医学科学院药物研究所 | 含有哌嗪酮的喹唑啉二酮盐类化合物、其制备方法、药物组合物和用途 |
TWI749881B (zh) * | 2019-11-21 | 2021-12-11 | 大陸商深圳信立泰藥業股份有限公司 | 二氧代哌類衍生物、其製備方法及其在醫藥上的應用 |
CN112608303B (zh) * | 2020-12-25 | 2021-10-26 | 华南理工大学 | 一种哌嗪类中间体及其制备方法与应用 |
CN114044769B (zh) * | 2021-11-25 | 2023-12-12 | 中山大学 | 一种β-吲哚喹唑啉酮衍生物及其制备方法和应用 |
Family Cites Families (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2027645A1 (de) | 1970-06-05 | 1971-12-09 | Byk Gulden Lomberg Chemische Fa bnk GmbH, 7750 Konstanz | Piperazinylalkyl chinazolon (4) den vate, Verfahren zu deren Herstellung und sie enthaltende Arzneimittel |
BE503170A (fr) | 1975-09-02 | |||
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
IL90858A (en) | 1988-07-07 | 1994-08-26 | Rhone Poulenc Sante | History (Aza) Naftalensultam, their preparation and preparations containing them |
DE4312832C1 (de) | 1993-04-20 | 1994-10-20 | Boehringer Ingelheim Kg | Verfahren zur Herstellung enantiomerenreiner Ketale der (S)- und (R)-3-Oxocyclopentancarbonsäure |
DE4316576A1 (de) | 1993-05-18 | 1994-11-24 | Boehringer Ingelheim Kg | Verbessertes Verfahren zur Herstellung von 1,3-Dipropyl-8-(3-Oxocyclopentyl)-xanthin |
US5589489A (en) | 1993-12-15 | 1996-12-31 | Zeneca Limited | Cyclic amide derivatives for treating asthma |
GB9904275D0 (en) | 1999-02-24 | 1999-04-21 | Cancer Res Campaign Tech | Anti-cancer compounds |
US20020082268A1 (en) | 2000-03-20 | 2002-06-27 | Yun Gao | Therapeutic compounds for the treatment of asthma and allergy, and methods of use thereof |
DK1178047T3 (da) | 2000-08-03 | 2004-05-24 | Pfizer Prod Inc | Diazabicyclooctanderivater og terapeutiske anvendelser deraf |
AUPR201600A0 (en) | 2000-12-11 | 2001-01-11 | Fujisawa Pharmaceutical Co., Ltd. | Quinazolinone derivative |
EP1396488A1 (fr) * | 2001-05-23 | 2004-03-10 | Mitsubishi Pharma Corporation | Compose heterocyclique condense et son utilisation medicale |
BR0211119A (pt) | 2001-07-11 | 2005-12-13 | Elan Pharm Inc | Composto, método de tratar um paciente que tenha, ou de prevenir um paciente de pegar, uma doença ou condição, uso de um composto, e, método para fabricar um composto |
AUPR975601A0 (en) | 2001-12-24 | 2002-01-31 | Fujisawa Pharmaceutical Co., Ltd. | Quinazolinone derivatives |
AUPS019702A0 (en) | 2002-01-29 | 2002-02-21 | Fujisawa Pharmaceutical Co., Ltd. | Condensed heterocyclic compounds |
AU2003262747A1 (en) | 2002-08-21 | 2004-03-11 | Cytokinetics, Inc. | Compounds, compositions, and methods |
GB0317466D0 (en) | 2003-07-25 | 2003-08-27 | Univ Sheffield | Use |
CN1266155C (zh) | 2003-08-01 | 2006-07-26 | 浙江震元制药有限公司 | 6-氯-4-羟基-2-甲基-2H-噻吩并(2,3-e)-1,2-噻嗪-1,1-二氧化物-3-羧酸酯的合成方法 |
BRPI0413595B8 (pt) | 2003-08-18 | 2021-05-25 | H Lundbeck As | sal de malonato, composição farmacêutica, uso de um sal de malonato, e, método de fabricação de um composto |
US20050065178A1 (en) | 2003-09-19 | 2005-03-24 | Anwer Basha | Substituted diazabicycloakane derivatives |
CA2547077C (fr) | 2003-12-01 | 2015-11-03 | Kudos Pharmaceuticals Limited | Inhibiteurs de reparation d'adn endommage pour le traitement du cancer |
US9016221B2 (en) | 2004-02-17 | 2015-04-28 | University Of Florida Research Foundation, Inc. | Surface topographies for non-toxic bioadhesion control |
JP4912145B2 (ja) | 2004-02-26 | 2012-04-11 | あすか製薬株式会社 | ピリミジン誘導体 |
US7381822B2 (en) | 2004-03-31 | 2008-06-03 | The General Hospital Corporation | Diagnostic and therapeutic alkyl piperidine/piperazine compounds and process |
US20050245534A1 (en) | 2004-04-29 | 2005-11-03 | Link James T | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme |
ZA200609259B (en) | 2004-04-30 | 2008-07-30 | Takeda Pharmaceutical | Heterocyclic amide compound and use thereof as an mmp-13 inhibitor |
JP4969443B2 (ja) | 2004-06-30 | 2012-07-04 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Parp阻害剤としてのキナゾリノン誘導体 |
WO2006039545A2 (fr) | 2004-09-30 | 2006-04-13 | Maxim Pharmaceuticals, Inc. | Utilisation d'inhibiteurs parp-1 permettant de proteger des lymphocytes tumoricides contre l'apoptose |
US20080076760A1 (en) | 2004-11-10 | 2008-03-27 | Wakamoto Pharmaceutical Co., Ltd | 2,3,4,5-tetrahydro-1h-1,5-benzodiazepine derivative and medicinal composition |
US20090099160A1 (en) | 2004-12-17 | 2009-04-16 | David Andrews | 4-(4-(Imidazol-4-Yl) Pyrimidin-2-Ylamino) Benzamides as CDK Inhibitors |
RU2412179C2 (ru) | 2005-03-23 | 2011-02-20 | Актелион Фармасьютиклз Лтд | Гидрированные производные бензо[с]тиофена в качестве иммуномодуляторов |
WO2006137510A1 (fr) | 2005-06-24 | 2006-12-28 | Ono Pharmaceutical Co., Ltd. | Agent pour réduire le saignement lors de troubles cérébrovasculaires |
US7300947B2 (en) | 2005-07-13 | 2007-11-27 | Banyu Pharmaceutical Co., Ltd. | N-dihydroxyalkyl-substituted 2-oxo-imidazole derivatives |
WO2007011623A1 (fr) | 2005-07-15 | 2007-01-25 | Schering Corporation | Derives de quinazoline utiles pour traiter le cancer |
WO2007062413A2 (fr) | 2005-11-25 | 2007-05-31 | University Of Medicine And Dentistry Of New Jersey | Utilisation d'inhibiteurs du parp-1 |
CA2634491A1 (fr) | 2005-12-21 | 2007-06-28 | Painceptor Pharma Corporation | Compositions et procedes de modulation de canaux ioniques commandes par porte |
WO2007076055A2 (fr) | 2005-12-22 | 2007-07-05 | Entremed, Inc. | Compositions et methodes comprenant l'utilisation d'antagonistes du recepteur active par des proteases |
CA2680789C (fr) | 2006-03-28 | 2016-02-16 | Atir Holding S.A. | Composes heterocycliques et leurs utilisations dans le traitement de troubles sexuels |
AU2007243457B2 (en) | 2006-04-26 | 2012-02-23 | F. Hoffmann-La Roche Ag | Pharmaceutical compounds |
WO2008080824A1 (fr) | 2006-12-29 | 2008-07-10 | F. Hoffmann-La Roche Ag | Cétales aromatiques sulfonés |
JPWO2009038064A1 (ja) | 2007-09-19 | 2011-01-06 | 株式会社医薬分子設計研究所 | I型11βヒドロキシステロイド脱水素酵素阻害活性を有する複素環誘導体 |
JP2009096804A (ja) | 2007-09-26 | 2009-05-07 | Santen Pharmaceut Co Ltd | キナゾリノン誘導体又はキノキサリン誘導体を有効成分として含む角結膜障害の予防又は治療剤 |
WO2009041566A1 (fr) | 2007-09-26 | 2009-04-02 | Santen Pharmaceutical Co., Ltd. | Prophylaxie ou thérapie de maladies du segment postérieur de l'oeil faisant intervenir un dérivé de quinazolinone ou un dérivé de quinoxaline comme principe actif |
JP2011507910A (ja) | 2007-12-21 | 2011-03-10 | ユニバーシティー オブ ロチェスター | 真核生物の寿命を変更するための方法 |
FR2926221A1 (fr) | 2008-01-14 | 2009-07-17 | Tassin Thomas | Compositions permettant la reproduction artificielle des conditions pharmacologiques de la dependance aux drogues addictives telles que opiaces, psychostimulants, tabac et alcool, par la combinaison de nicotine et d'un ligand. |
WO2009114459A2 (fr) | 2008-03-10 | 2009-09-17 | The Trustees Of The University Of Pennsylvania | Régime thérapeutique antinéoplasique combiné comprenant la co-disruption de la voie parp et du complexe mre11/rad50/nbs1, et compositions utiles à cette fin |
AU2009324210A1 (en) | 2008-12-05 | 2010-06-10 | F. Hoffmann-La Roche Ag | Pyrrolopyrazinyl urea kinase inhibitors |
WO2010082813A1 (fr) | 2009-01-13 | 2010-07-22 | Academisch Medisch Centrum Bij De Universiteit Van Amsterdam | Procédé de traitement du cancer |
RU2568611C2 (ru) | 2010-03-25 | 2015-11-20 | Эббви Инк. | Средства, индуцирующие апоптоз, для лечения рака, иммунных и аутоиммунных заболеваний |
PL2611300T3 (pl) | 2010-09-03 | 2016-10-31 | Podstawione skondensowane pochodne dihydropirymidynonów |
-
2013
- 2013-07-09 CA CA2877826A patent/CA2877826C/fr not_active Expired - Fee Related
- 2013-07-09 WO PCT/IB2013/055618 patent/WO2014009872A1/fr active Application Filing
- 2013-07-09 AU AU2013288265A patent/AU2013288265B2/en not_active Ceased
- 2013-07-09 EP EP13742752.2A patent/EP2870140B8/fr not_active Not-in-force
- 2013-07-09 IN IN2MUN2015 patent/IN2015MN00002A/en unknown
- 2013-07-09 ES ES13742752.2T patent/ES2595240T3/es active Active
- 2013-07-09 US US14/411,968 patent/US9359367B2/en not_active Expired - Fee Related
-
2014
- 2014-12-23 ZA ZA2014/09497A patent/ZA201409497B/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP2870140B1 (fr) | 2016-07-27 |
EP2870140A1 (fr) | 2015-05-13 |
US9359367B2 (en) | 2016-06-07 |
CA2877826C (fr) | 2016-08-16 |
US20150152118A1 (en) | 2015-06-04 |
ES2595240T3 (es) | 2016-12-28 |
EP2870140B8 (fr) | 2016-09-28 |
AU2013288265A1 (en) | 2015-01-29 |
ZA201409497B (en) | 2015-12-23 |
WO2014009872A1 (fr) | 2014-01-16 |
CA2877826A1 (fr) | 2014-01-16 |
AU2013288265B2 (en) | 2017-04-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12018500360A1 (en) | Heteroaryl derivatives as parp inhibitors | |
IN2015MN00002A (fr) | ||
PH12018500041A1 (en) | Substituted aza compoounds as irak-4 inhibitors | |
PH12018500040A1 (en) | Indazole and azaindazole compounds as irak-4 inhibitors | |
PH12015501517A1 (en) | Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease | |
PH12016502382A1 (en) | Substituted indazole compounds as irak4 inhibitors | |
MX352672B (es) | Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer. | |
MX2023001876A (es) | Derivados de rapamicina. | |
SA515360469B1 (ar) | مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها | |
MX368703B (es) | Un inhibidor de mdm2 derivado de acido benzoico para el tratamiento del cancer. | |
PH12017500007A1 (en) | Quinolizinone derivatives as p13k inhibitors | |
MD4659B1 (ro) | Polimorf al inhibitorilor SYK | |
MX2011009796A (es) | Inhibidores de la cinasa pi3. | |
MX2014014106A (es) | Derivados de acido 7-oxo-tiazolopiridinocarbonico y su uso en el tratamiento, disminucion o prevencion de una enfermedad viral. | |
MX363605B (es) | Compuestos bicíclicos fusionados de azaindazol o diazaindazol para usarse en el tratamiento o prevención del dolor. | |
MX2013011591A (es) | Métodos y composiciones para tratar enfermedades neurodegenerativas. | |
NZ700283A (en) | Substituted pyridopyrimidine compounds and their use as flt3 inhibitors | |
WO2014155300A3 (fr) | Dérivés pyrimidine aminée substitués en tant qu'inhibiteurs de tak-1 | |
MX2013012588A (es) | Inhibidores de cinasa. | |
CA2881554C (fr) | Methodes d'inhibition de la fascine | |
MX2014003801A (es) | Derivados de pirimidin-4-ona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral. | |
NZ706591A (en) | Oxazolidin-2-one-pyrimidine derivatives | |
NZ726695A (en) | Gls1 inhibitors for treating disease | |
MX2015008288A (es) | Derivados de piridona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral. | |
MX362896B (es) | Cis-morfolinona y otros compuestos como inhibidores de mdm2 para el tratamiento del cáncer. |